Immunovia AB (OTCPK:IMMVF)
$ 0.07382 0 (0%) Market Cap: 8.20 Mil Enterprise Value: 3.48 Mil PE Ratio: 0 PB Ratio: 2.76 GF Score: 49/100

Q2 2021 Immunovia AB (publ) Earnings Call Transcript

Aug 19, 2021 / 02:30PM GMT
Release Date Price: $19.69
Operator

Welcome to the Immunovia Audiocast Teleconference Q2 2021. (Operator Instructions) I'll now hand the floor to CEO, Patrik Dahlen. Please begin your meeting.

Patrik Dahlen;publ;CEO
Immunovia AB

()-

Good afternoon, everyone. Thanks for joining us today, and thank you for your continued interest in Immunovia. Today's quarterly report presentation is a historical one as it is the first presentation as a commercial company.

We have now passed a pivotal milestone in the company's history. Immunovia Inc. has launched IMMray PanCan-d as a laboratory-developed test in the U.S. This is a major achievement for all of us here at Immunovia and provides an opportunity for doctors, patients and their relatives to access the first blood test for early detection of pancreatic cancer. It is truly groundbreaking.

My name is Patrik Dahlen. I am the CEO of Immunovia, and I will be presenting the quarter 2, 2021 results for Immunovia. Together with me on the call is also our Medical Director, Dr. Thomas King; and Cindy Callahan, our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot